Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells

Scandinavian Journal of Immunology

Volumn 71, Issue 2, 2010, Pages 91-98

  Nowak, M ^a   Klink, M ^b   Glowacka, E ^a   Sulowska, Z ^b   Kulig, A ^a   Szpakowski, M ^a   Szyllo, K ^a   Tchorzewski, H ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BENIGN TUMOR; CANCER CELL; CANCER PATIENT; CANCER STAGING; CELL ACTIVATION; CELL CONTACT; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; OVARY CANCER; OVARY TUMOR; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION;

ADULT; AGED; CELL COMMUNICATION; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 75149171435     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02350.x     Document Type: Article

References (36)

1. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006 16: 3 15.
2. Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp 2006 54: 323 333.
3. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology 2006 117: 433 442.
4. Lukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn 2007 117: 247 251.
5. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-α as a tumour promoter. Eur J Cancer 2006 42: 745 750.
6. Glezerman M, Maymon E, Piura B et al. Tumor necrosis factor-alpha and interleukin-6 are differently expressed by fresh human cancerous ovarian tissue and primary cell lines. Eur Cytokine Netw 1998 9: 171 179.
7. Wang Y, Yang J, Gao Y et al. Regulatory effect of E2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol 2005 2: 365 372.
8. Balkwill F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev 2006 25: 409 416.
9. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005 54: 721 728.
10. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008 264: 204 215.
11. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008 66: 1 9.
12. Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 2005 67: 35 50.
13. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002 8: 3137 3145.
14. Asselin-Paturel C, Echchakir H, Carayol G et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 1998 77: 7 12.
15. Benedet JL, Bender H, Jones H III., Ngan HYS, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 2000 70: 209 262.
16. Klink M, Jastrzembska K, Nowak M et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol 2008 68: 328 336.
17. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997 66: 27 30.
18. Santin AD, Bellone S, Ravaggi A et al. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2001 108: 804 808.
19. Mustea A, Könsgen D, Braicu EI et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 2006 26: 1715 1718.
20. Mustea A, Braicu EI, Koensgen D et al. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine 2009 45: 8 11.
21. Daraï E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod 2003 18: 1681 1685.
22. Toutirais O, Chartier P, Dubois D et al. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003 14: 246 255.
23. Offner FA, Obrist P, Stadlmann S et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995 7: 542 547.
24. Zhou J, Ye F, Chen H, Lv W, Gan N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 2007 35: 290 300.
25. Marth C, Fiegl H, Zeimet AG et al. Interferon-γ expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004 191: 1598 1605.
26. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999 163: 6251 6260.
27. + T cells. Immunity 2005 22: 371 383.
28. Wall L, Burke F, Smyth JF, Balkwill F. The anti-proliferative activity of interferon-γ on ovarian cancer: in vitro and in vivo. Gynecol Oncol 2003 88: S149 51.
29. Jakowlew SB. Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev 2006 25: 435 457.
30. Broderick L, Bankert RB. Membrane-associated TGF-β1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J Immunol 2006 177: 3082 3088.
31. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005 11: 937s 43s.
32. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007 102: 129 135.
33. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001 12: 33 40.
34. Burger RA, Grosen EA, Ioli GR et al. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J Interferon Cytokine Res 1995 15: 255 260.
35. Chernoff AE, Granowitz EV, Shapiro L et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995 154: 5492 5499.
36. Gross S, Walden P. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett 2008 116: 7 14.